New Reference Standard: Retatrutide, TLC No. PR-178001, CAS# 2381089-83-2

We are pleased to announce the availability of Retatrutide (PR-178001), a high-quality peptide reference standard now available from stock to support analytical and research applications.

Retatrutide is a next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently under clinical investigation for metabolic and cardiometabolic indications. Given its structural complexity and increasing scientific and regulatory interest, reliable analytical characterization is essential for research and method development activities.

Our Retatrutide reference standard has been carefully purified and extensively characterized to ensure high chemical purity, as detailed in the accompanying certificate of analysis (COA). The material is suitable for use in analytical method development, system suitability testing, assay calibration, LC-MS/MS applications, and related research studies requiring well-characterized reference materials.

Due to the complexity of long peptide sequences and the analytical challenges associated with their purification and characterization, sourcing material of consistent and reliable quality can be difficult. Our current batch is available from stock for immediate shipment.

In addition, we are currently developing a Retatrutide-d7 stable isotope-labeled analog, which is in production and expected to be available in the near future. This SIL version is intended to support LC-MS/MS bioanalytical method development and quantitative applications requiring a robust internal standard.

Please contact us for availability, technical details, or a quotation.

New Stable Isotope-Labeled Reference Standard: Minocycline-d6 Ditrifluoroacetate

We are pleased to announce the successful development of Minocycline-d6 Ditrifluoroacetate, a technically challenging stable isotope-labeled (SIL) reference standard.

Minocycline is a broad-spectrum tetracycline antibiotic widely used in pharmaceutical development and clinical research. This d6-labeled analog is intended to support analytical and bioanalytical studies related to minocycline, including LC-MS/MS method development, validation, and quantitative analysis.

This material has been produced with exceptional quality, offering 99.5% isotopic purity and >98.5% chemical purity in the current batch (COA). The high isotopic purity minimizes isotopic overlap and analytical interference, supporting accurate internal standard performance in LC-MS/MS–based PK and bioanalytical assays. This level of quality helps enable robust, reproducible data generation and supports defensible data packages under GLP conditions, reducing the risk of regulatory questions related to isotopic overlap or analytical interference.

Due to the complexity of synthesis and the challenge of achieving high isotopic purity, this compound is difficult to source at this quality level. Please contact us for availability and a quotation.

TLC Named “Company of the Year – Canada 2025” by Pharma Tech Outlook Magazine

We’re proud to share that TLC has been recognized as the Custom Synthesis Organic Compounds Manufacturing Company of the Year – Canada 2025 by Pharma Tech Outlook Magazine.

This honor follows an extensive evaluation by industry experts, C-level executives, and the publication’s editorial board, supported by numerous subscriber nominations highlighting TLC’s reputation, scientific excellence, and consistent performance under pressure.

Featured as the cover story in Pharma Tech Outlook’s Pharma Manufacturing latest issue, the article showcases TLC’s role as a trusted synthesis partner helping pharmaceutical companies navigate complex regulatory and development challenges.

Read the full article:

CPHI North America 2024

TLC will be participating in CPHI North America, in Philadelphia from May 7th to May 9th, 2024. Mark your calendars, and be sure to stop by Booth #716 to say hello and discover how TLC can meet your needs.

Focus on Nitrosamine Impurities

Since the FDA's 2018 report and subsequent recall of nitrosamine-contaminated drugs, the global pharmaceutical industry has grappled with evolving testing standards imposed by regulators worldwide.

In response, TLC has substantially grown its portfolio of these impurities, now offering over 1000 such substances in our catalog, many of which are available from stock and ready to ship.

Our unwavering dedication to enhancing safety persists as we consistently introduce new impurities to our catalog, aiding the pharmaceutical sector in tackling this pressing concern.

CPHI India 2023

TLC will be exhibiting at CPHI India in Greater Noida, Delhi from November 28-30, 2023. Our team would welcome the opportunity to meet you at booth # 2.D36!

CPHI North America 2023

TLC will be attending CPHI North America in Philadelphia from April 25-27, 2023. Our team would welcome the opportunity to meet you at booth #1047!

ISO certification

In support of our continued commitment to excellence in Quality, TLC has successfully obtained ISO 17025:2017 accreditation.

COVID-19 Response

At TLC our top priority during the current global COVID-19 pandemic is the health and safety of our employees, our customers and our community.
We are following all government recommendations in our facilities to insure a safe working environment for our staff and will be continuing to supply our customers with crucial standards they need to move their research forward.
TLC is proud to do our part in the community to help fight this pandemic. We will be donating $100,000 worth of crucial supplies for front line health workers, to whom we extend our utmost thanks.

Shanghai New Int’l centre (SNIEC), Shanghai China

CPHI China

We are pleased to be attending CPHI China once more! Our sales and technical team welcome the opportunity to meet you at booth E1N36, where we will be glad to demonstrate how TLC can support and improve your present and future reference Standards needs. We look forward to seeing you there!

TLC is pleased to announce the launch of Peptide Chemistry Laboratory

In order to meet the growing need and demand in the Pharmaceutical Industry, TLC is proud to announce the addition of Peptides and related compounds synthesis to our existing line of products.
A new Laboratory has been established with experienced scientists and equipment solely dedicated to synthesizing the reference standards for therapeutic peptide drugs.

Shanghai New Int'l Centre (SNIEC), Shanghai, China

CPHI China

Come meet our sales and technical team at booth #T2C01​ to discuss how TLC can support and improve on your present and future Reference Standards needs.